Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
This study will explore whether ivabradine lowers heart rate, and thus improves exercise capacity, in survivors of lymphoma who have an elevated resting heart rate as a side effect of prior radiation treatment. The drugs involved in this study are: * Ivabradine * Placebo
• Survivors of mediastinal lymphoma (either Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma) with no active malignancy
• Prior mediastinal or mantle radiation ≥ 5 years prior to enrollment in the study
• Age 18-80 years.
• Participants must have normal organ function as defined below:
‣ AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
⁃ creatinine clearance ≥ 15 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
• Normal sinus rhythm with resting heart rate ≥ 80 bpm on screening EKG
• Based on findings in animals, ivabradine may cause fetal harm when administered to a pregnant woman. For this reason, women of child-bearing potential must agree to use adequate contraception.
• Ability to understand and the willingness to sign a written informed consent document